SLRX – salarius pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Salarius Pharmaceuticals (NASDAQ:SLRX) is now covered by analysts at Weiss Ratings. They set a "sell (e+)" rating on the stock.
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” [Yahoo! Finance]
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: HANISH ARNOLD C
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Marschel Peter Klaus
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Hibner Barbara Louise
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: PIERCE FREDERICK II
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: Rosenblum Mark J
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.